OIEPX
Price
$23.30
Change
-$0.58 (-2.43%)
Updated
Dec 18 closing price
RMFCX
Price
$54.22
Change
-$1.42 (-2.55%)
Updated
Dec 18 closing price
Ad is loading...

OIEPX vs RMFCX

Header iconOIEPX vs RMFCX Comparison
Open Charts OIEPX vs RMFCXBanner chart's image
JPMorgan Equity Income R3
Price$23.30
Change-$0.58 (-2.43%)
VolumeN/A
CapitalizationN/A
American Funds American Mutual R3
Price$54.22
Change-$1.42 (-2.55%)
VolumeN/A
CapitalizationN/A
OIEPX vs RMFCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
OIEPX vs. RMFCX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OIEPX is a Sell and RMFCX is a Buy.

FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 98.7B vs. OIEPX (45.1B). OIEPX (1.71) and RMFCX (1.69) have matching dividends . OIEPX was incepted earlier than RMFCX: OIEPX (8 years) vs RMFCX (23 years). RMFCX is a more actively managed with annual turnover of: 25.00 vs. OIEPX (8.00). OIEPX has a lower initial minimum investment than RMFCX: OIEPX (0) vs RMFCX (250). RMFCX annual gain was more profitable for investors over the last year : 12.63 vs. OIEPX (8.77). RMFCX return over 5 years is better than : 40.39 vs. OIEPX (34.67).
OIEPXRMFCXOIEPX / RMFCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years23 years-
Gain YTD7.80011.42368%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets45.1B98.7B46%
Annual Yield % from dividends1.711.69101%
Returns for 1 year8.7712.6369%
Returns for 3 years8.8714.1663%
Returns for 5 years34.6740.3986%
Returns for 10 yearsN/A61.84-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REKR0.83N/A
-0.01%
Rekor Systems
CRBG29.99-0.44
-1.45%
Corebridge Financial
WHD61.48-1.46
-2.32%
Cactus
ABCL2.79-0.07
-2.45%
AbCellera Biologics
TRIB0.85-0.05
-5.67%
Trinity Biotech plc